Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(0.12) per share.
Inspira Technologies Reports Q4 2022 And FY Financial Results; As Of December 31, 2022, The Company Had $13.9M In Cash, Cash Equivalents, And Deposits
Financial results for the twelve months ended December 31, 2022
Research and development expenses for the twelve months ended December 31, 2022, were $8 million, compared to $3.9 million in
